View published articles from peer-reviewed journals

2022

True
Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA.
PharmacoEconomics 40, 979–988 (2022).
Chen, J.V., Gahn, J.C., Nesheim, J. et al.
True
Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Journal of Medical Economics 2022, 25:1, 1092-1100
Jing Voon Chen, Timothy M. Klein, Jeffrey Nesheim & Paul N. Mudd Jr
True
Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors
Curr Ther Res. 2022
Brucker et al.
True
Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities: A Perspective from Directors of Nursing
J Gerontol Nurs. 2022
Stefanacci RG et al.
False
Vibegron for the treatment of patients with dry and wet overactive bladder: a subgroup analysis from the EMPOWUR trial.
Int J Clin Pract. 2022;2022:(9 pages). doi:10.1155/2022/6475014
Staskin D, Frankel J, Varano S, et al.
False
An evaluation of the efficacy and safety of vibegron in the treatment of overactive bladder.
Ther Clin Risk Manag. 2022;18:171-182. doi:10.2147/TCRM.S310371
Frankel J, Staskin D, Varano S, Kennelly MJ, Jankowich RA, Haag-Molkenteller C.
False
Interpretation of the meaningfulness of symptom reduction with vibegron in patients with overactive bladder: analyses from EMPOWUR.
Adv Ther. 2022;39:959-970. doi:10.1007/s12325-021-01972-8
Frankel J, Staskin D, Varano S, et al.
False
Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind, placebo-controlled trial.
Blood Press Monit. 2022;27(2):128-134. doi:10.1097/MBP.0000000000000572
Weber MA, Haag-Molkenteller C, King J, Walker A, Mudd Jr PN, White WB.

2021

True
Efficacy of vibegron and mirabegron for overactive bladder: A systematic literature review and indirect treatment comparison.
Kennelly et al. Adv Ther. 2021
Kennelly et al.
True
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug-Drug Interactions
Clin Drug Investig. 2021
Rutman et al.
True
Overactive Bladder Health Care Burden in the US Long-Term Care Setting: A Retrospective Cohort Study
J Clin Pathways. 2021
Stefanacci RG et al.
True
Gene Therapy for Overactive Bladder: A Review of BK-Channel α-Subunit Gene Transfer
Ther Clin Risk Manag. 2021
Andersson et al.
False
Vibegron improves quality-of-life measures in patients with overactive bladder: patient-reported outcomes from the EMPOWUR study.
Int J Clin Pract. 2021;75(5):e13937. doi:10.1111/ijcp.13937
Frankel J, Varano S, Staskin D, Shortino D, Jankowich R, Mudd PN Jr.
False
Efficacy and safety of once-daily vibegron for treatment of overactive bladder in patients aged ≥65 and ≥75 years: subpopulation analysis from the EMPOWUR randomized, international, phase Ill study.
Drugs Aging. 2021;38:137-146. doi:10.1007/s40266-020-00829-z
Varano S, Staskin D, Frankel J, Shortino D, Jankowich R, Mudd PN Jr.

2020

True
Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta‐analysis
Neurourol Urodyn. 2020
Dmochowski et al.
True
Optimizing Nonsurgical Treatments of Overactive Bladder in the United States
Urology 2020
Brucker et al.
True
Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor...
Neurourol Urodyn. 2020
Rover et al.
False
Once-daily vibegron 75 mg for overactive bladder: long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).
J Urol. Published online December 28, 2020. doi:10.1097/JU.0000000000001574
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN. 
False
Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis.
Int Urol Nephrol. 2020;52(12):2215-2221. doi:10.1007/s11255-020-02536-5
Jian Z, Yuan C, Li H, Zhang W, Wang K.
False
Evaluating vibegron for the treatment of overactive bladder.
Expert Opin Pharmacother. 2020 Sep 29:1-9. [Epub ahead of print] doi:10.1080/14656566.2020.1809652
Rechberger T, Wróbel A.
False
International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR.
J Urol. 2020;204(2):316-324. doi:10.1097/JU.0000000000000807
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr.
False
Effects of vibegron, a novel β3-adrenoceptor agonist, and its combination with imidafenacin or silodosin in a rat with partial bladder outlet obstruction.
Eur J Pharmacol. Published online July 5, 2020. doi:10.1016/j.ejphar.2020.173096
Maruyama I, Yamamoto S, Tsuchioka K, Yamazaki T.
False
The efficacy and safety of vibegron in treating overactive bladder: a systematic review and pooled analysis of randomized controlled trials.
Neurourol Urodyn. 2020;39(5):1255-1263. doi:10.1002/nau.24387
Shi H, Chen H, Zhang Y, Cui Y.
False
Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
BJU Int. 2020;125(5):709-717. doi:10.1111/bju.15020
Yoshida M, Takeda M, Gotoh M, et al.

2019

False
Efficacy of novel β3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: a post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study.
Int J Urol. 2019;26(3):369-375. doi:10.1111/iju.13877
Yoshida M, Takeda M, Gotoh M, et al.
False
Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats.
Eur J Pharmacol. Published online December 1, 2019. doi:10.1016/j.ejphar.2019.172727
Yamazaki T, Maruyama I.
False
Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial.
Eur Urol. 2019;75(2):274-282. doi:10.1016/j.eururo.2018.10.006
Mitcheson HD, Samanta S, Muldowney K, et al.

2018

False
Vibegron: first global approval.
Drugs. 2018;78(17):1835-1839. doi:10.1007/s40265-018-1006-3
Keam SJ.
False
Synthesis of vibegron enabled by a ketoreductase rationally designed for high pH dynamic kinetic reduction.
Angew Chem Int Ed Engl. 2018;57(23):6863-6867. doi:10.1002/anie.201802791
Xu F, Kosjek B, Cabirol FL, et al.
False
Vibegron, a novel potent and selective β3-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study.
Eur Urol. 2018;73(5):783-790. doi:10.1016/j.eururo.2017.12.022
Yoshida M, Takeda M, Gotoh M, Nagai S, Kurose T.
False
Long‐term safety and efficacy of the novel β3‐adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study.
Int J Urol. 2018;25(7):668-675. doi:10.1111/iju.13596
Yoshida M, Kakizaki H, Takahashi S, Nagai S, Kurose T.

2017

False
2D-QSAR and 3D-QSAR/CoMSIA studies on a series of (R)-2-((2-(1H-indol-2-yl)ethyl)amino)-1-phenylethan-1-ol with human β3-adrenergic activity.
Molecules. 2017;22(3):404. doi:10.3390/molecules2203040
Apablaza G, Montoya L, Morales-Verdejo C, et al.
False
Pharmacological characterization of a novel beta 3 adrenergic agonist, vibegron: evaluation of antimuscarinic receptor selectivity for combination therapy for overactive bladder.
J Pharmacol Exp Ther. 2017;360(2):346-355. doi:10.1124/jpet.116.237313
Di Salvo J, Nagabukuro H, Wickham LA, et al.

2016

False
Discovery of vibegron: a potent and selective β3-adrenergic receptor agonist for the treatment of overactive bladder.
J Med Chem. 2016;59(2):609-623. doi:10.1021/acs.jmedchem.5b01372
Edmondson SD, Zhu C, Kar NM, et al.

Search results (0 results)

Try adjusting your keyword(s). Separate each keyword with a comma. You can also submit a question, or contact Urovant Medical Affairs at 833-UROVANT.

Documents obtained from search may contain information that is not included in the approved product labeling. Urovant does not endorse the use of its products in a manner not consistent with the approved label. Please refer to the full product labeling for complete prescribing information and important safety information.

Tell us what interests you

How interested are you in learning more about the following topics?

The hypothetical role of targeted gene therapy in modulating BK channel expression
The role of beta-3 adrenergic receptor agonists in the treatment of patients with OAB
A comprehensive treatment overview for OAB
Treatment approaches in OAB
Recent publications on vibegron and OAB

Success!

We’ve received your completed survey. Thanks for participating.

Close

Thank You.

We’ve received your inquiry. Thank you for contacting Urovant Sciences Medical Affairs. We will contact you shortly.

Close

Take Survey

Welcome to
Urovant Sciences Medical Affairs

This site is intended as an educational resource for U.S. healthcare providers. The content may include information about products or potential uses that have not been approved by the U.S. Food and Drug Administration.

This information is not intended to be promotional or deliver medical advice.

Choose an option:

I’m a U.S. healthcare professional I’m a U.S. patient or caregiver